Nanthealth LLC (NYSE:NH) shares dropped 6.2% during mid-day trading on Wednesday . The company traded as low as $9.79 and last traded at $10.05, with a volume of 55,680 shares changing hands. The stock had previously closed at $10.71.

NH has been the subject of a number of analyst reports. Cowen and Company initiated coverage on Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $19.00 price objective for the company. Jefferies Group initiated coverage on Nanthealth in a research report on Monday, June 27th. They set a “buy” rating for the company. Canaccord Genuity initiated coverage on Nanthealth in a research report on Monday, June 27th. They set a “buy” rating and a $17.00 price objective for the company. FBR & Co initiated coverage on Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, First Analysis initiated coverage on Nanthealth in a research report on Monday, June 27th. They set an “overweight” rating and a $18.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $18.00.

The firm’s market capitalization is $5.80 billion. The stock has a 50-day moving average price of $13.19 and a 200 day moving average price of $13.19.

In other news, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was purchased at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the acquisition, the insider now directly owns 15,000,000 shares in the company, valued at approximately $210,000,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Patrick Soon-Shiong purchased 357,143 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.